Targeting the EGFR signaling pathway in cancer therapy

Bibliography

• Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46
   PubMed Web of Science ®Google Scholar
• Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67
   PubMed Web of Science ®Google Scholar
• Ferguson KM, Berger MB, Mendrola JM, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003;11:507-17
   PubMed Web of Science ®Google Scholar
• Ogiso H, Ishitani R, Nureki O, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002;110:775-87
   PubMed Web of Science ®Google Scholar
• Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002;297:1330-3
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002;110:763-73
   PubMed Web of Science ®Google Scholar
• Bouyain S, Longo PA, Li S, The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 2005;102:15024-9
   PubMed Web of Science ®Google Scholar
• Dawson JP, Berger MB, Lin CC, Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 2005;25:7734-42
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Chakraborty S, MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 2008;68:2065-70
   PubMed Web of Science ®Google Scholar
• Ponnusamy MP, Singh AP, Jain M, MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer 2008;99:520-6
   PubMed Web of Science ®Google Scholar
• Normanno N, De LA, Bianco C, Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
   PubMed Web of Science ®Google Scholar
• Siwak DR, Carey M, Hennessy BT, Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010;2010:568938
   PubMedGoogle Scholar
• Tzahar E, Waterman H, Chen X, A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87
   PubMed Web of Science ®Google Scholar
• Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002;16:1041-63
   PubMed Web of Science ®Google Scholar
• Madshus IH, Stang E. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J Cell Sci 2009;122:3433-9
   Google Scholar
• Roepstorff K, Grovdal L, Grandal M, Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol 2008;129:563-78
   PubMed Web of Science ®Google Scholar
• Nesterov A, Wiley HS, Gill GN. Ligand-induced endocytosis of epidermal growth factor receptors that are defective in binding adaptor proteins. Proc Natl Acad Sci USA 1995;92:8719-23
   Google Scholar
• Lamaze C, Schmid SL. The emergence of clathrin-independent pinocytic pathways. Curr Opin Cell Biol 1995;7:573-80
   PubMed Web of Science ®Google Scholar
• Jiang X, Sorkin A. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 2003;4:529-43
   PubMedGoogle Scholar
• Levkowitz G, Waterman H, Ettenberg SA, Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999;4:1029-40
   PubMed Web of Science ®Google Scholar
• Waterman H, Katz M, Rubin C, A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 2002;21:303-13
   PubMed Web of Science ®Google Scholar
• Grovdal LM, Stang E, Sorkin A, Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004;300:388-95
   PubMed Web of Science ®Google Scholar
• Huang F, Goh LK, Sorkin A. EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci USA 2007;104:16904-9
   PubMed Web of Science ®Google Scholar
• Barriere H, Nemes C, Du K, Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery. Mol Biol Cell 2007;18:3952-65
   PubMedGoogle Scholar
• Lenferink AE, Pinkas-Kramarski R, van de Poll ML, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-97
   PubMed Web of Science ®Google Scholar
• Decker SJ. Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun 1990;166:615-21
   PubMed Web of Science ®Google Scholar
• Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 1991;2:599-612
   PubMedGoogle Scholar
• Lin SY, Makino K, Xia W, Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-8
   PubMed Web of Science ®Google Scholar
• Edwards JG, Swinson DE, Jones JL, EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006;54:399-407
   PubMed Web of Science ®Google Scholar
• Hoshino M, Fukui H, Ono Y, Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 2007;74:15-21
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006;95:211-18
   PubMed Web of Science ®Google Scholar
• Marti U, Burwen SJ, Wells A, Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991;13:15-20
   PubMed Web of Science ®Google Scholar
• Ni CY, Yuan H, Carpenter G. Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage. J Biol Chem 2003;278:4561-5
   PubMed Web of Science ®Google Scholar
• Offterdinger M, Schofer C, Weipoltshammer K, c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002;157:929-39
   PubMed Web of Science ®Google Scholar
• Psyrri A, Yu Z, Weinberger PM, Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-62
   PubMed Web of Science ®Google Scholar
• Wang SC, Lien HC, Xia W, Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-61
   PubMed Web of Science ®Google Scholar
• Xia W, Wei Y, Du Y, Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009;48:610-17
   PubMed Web of Science ®Google Scholar
• Xie Y, Hung MC. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 1994;203:1589-98
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005;280:31182-9
   PubMed Web of Science ®Google Scholar
• Lo HW, Ali-Seyed M, Wu Y, Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006;98:1570-83
   PubMed Web of Science ®Google Scholar
• Ni CY, Murphy MP, Golde TE, Gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81
   PubMed Web of Science ®Google Scholar
• Lo HW, Xia W, Wei Y, Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65:338-48
   PubMed Web of Science ®Google Scholar
• Hanada N, Lo HW, Day CP, Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 2006;45:10-17
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Ali-Seyed M, Nuclear interaction of EGFR and. STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005;7:575-89
   PubMed Web of Science ®Google Scholar
• Huo L, Wang YN, Xia W, RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci USA 2010;107:16125-30
   PubMed Web of Science ®Google Scholar
• Bareschino MA, Schettino C, Troiani T, Erlotinib in cancer treatment. Ann Oncol 2007;18(Suppl 6):vi35-41; vi35-vi41
   Google Scholar
• Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004;15:831-8
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011;26:823-33
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S. Anti-EGFR–targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis. Head & Neck 2011; doi: 10.1002/hed.21858
   Google Scholar
• Rocha-Lima CM, Soares HP, Raez LE, EGFR targeting of solid tumors. Cancer Contr 2007;14:295-304
   PubMedGoogle Scholar
• Burgess AW, Cho HS, Eigenbrot C, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52
   PubMed Web of Science ®Google Scholar
• Sunada H, Magun BE, Mendelsohn J, Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986;83:3825-9
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T, Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007;98:1275-80
   PubMed Web of Science ®Google Scholar
• Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991;9:553-62
   PubMed Web of Science ®Google Scholar
• van Krieken JH, Jung A, Kirchner T, KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31
   PubMed Web of Science ®Google Scholar
• Coutinho AK, Rocha Lima CM. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Contr 2003;10:224-38
   PubMedGoogle Scholar
• Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003;2:246-51
   Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14
   PubMed Web of Science ®Google Scholar
• Raben D, Helfrich B, Ciardiello F, Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer 2003;41(Suppl 1):S15-22
   Google Scholar
• Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9
   PubMed Web of Science ®Google Scholar
• Perrotte P, Matsumoto T, Inoue K, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23
   PubMed Web of Science ®Google Scholar
• Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29:47-50
   PubMed Web of Science ®Google Scholar
• Hecht JR, Patnaik A, Berlin J, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8
   PubMed Web of Science ®Google Scholar
• Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000;60(Suppl 1):25-32
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001;28:67-79
   PubMed Web of Science ®Google Scholar
• Hu JC, Sadeghi P, Pinter-Brown LC, Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-26
   PubMed Web of Science ®Google Scholar
• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-19
   PubMed Web of Science ®Google Scholar
• Widakowich C, de CG Jr, de AE, Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-55
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Barker AJ, Davies DH, Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996;38:67-73
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50
   PubMed Web of Science ®Google Scholar
• Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30:255-68
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001;13:491-8
   PubMed Web of Science ®Google Scholar
• Moulder SL, Yakes FM, Muthuswamy SK, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95
   PubMed Web of Science ®Google Scholar
• Normanno N, Maiello MR, De LA. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-19
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Zakowski MF, Miller VA, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92
   PubMed Web of Science ®Google Scholar
• Natale RB. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clin Lung Cancer 2003;5(Suppl 1):S11-17
   Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48
   PubMed Web of Science ®Google Scholar
• Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004;90:2250-5
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004;6(Suppl 1):S20-3
   PubMedGoogle Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol 2003;1:466-72
   Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52
   PubMed Web of Science ®Google Scholar
• Herbst RS, Fukuoka M, Baselga J. Gefitinib–a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Zhang XT, Li LY, Wang SL, Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib. Chin Med J (Engl) 2005;118:1661-4
   Google Scholar
• Rusnak DW, Lackey K, Affleck K, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30:1426-47
   PubMed Web of Science ®Google Scholar
• Kroep JR, Ouali M, Gelderblom H, First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 2011;22:207-14
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Pegram MD, Tan-Chiu E, Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20:1026-31
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
   PubMed Web of Science ®Google Scholar
• Johnston SR. Are current drug development programmes realising the full potential of new agents? The scenario. Breast Cancer Res 2009;11(Suppl 3):S21
   Google Scholar
• Agulnik M, Cohen EW, Cohen RB, Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007;25:3978-84
   PubMed Web of Science ®Google Scholar
• Smaill JB, Palmer BD, Rewcastle GW, Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem 1999;42:1803-15
   PubMed Web of Science ®Google Scholar
• Fry DW, Bridges AJ, Denny WA, Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7
   PubMed Web of Science ®Google Scholar
• Fry DW. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 2000;15:3-16
   PubMedGoogle Scholar
• Nyati MK, Maheshwari D, Hanasoge S, Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004;10:691-700
   PubMed Web of Science ®Google Scholar
• Ako E, Yamashita Y, Ohira M, The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncol Rep 2007;17:887-93
   Google Scholar
• Trinks C, Djerf EA, Hallbeck AL, The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells. Biochem Biophys Res Commun 2010;393:6-10
   Google Scholar
• Nelson JM, Fry DW. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 2001;276:14842-7
   PubMedGoogle Scholar
• Gieseg MA, de BC, Ferguson LR, Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001;12:683-90
   PubMed Web of Science ®Google Scholar
• Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000;48:1519-28
   PubMed Web of Science ®Google Scholar
• Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28:80-5
   PubMed Web of Science ®Google Scholar
• Allen LF, Lenehan PF, Eiseman IA, Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29:11-21
   PubMed Web of Science ®Google Scholar
• Batra SK, Castelino-Prabhu S, Wikstrand CJ, Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6:1251-9
   PubMedGoogle Scholar
• Lee JC, Vivanco I, Beroukhim R, Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006;3:e485
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46
   PubMed Web of Science ®Google Scholar
• Sequist LV, Joshi VA, Janne PA, Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006;12:4403s-8s
   Google Scholar
• Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96
   PubMed Web of Science ®Google Scholar
• Adjei AA. K-ras as a target for lung cancer therapy. J Thorac Oncol 2008;3:S160-3
   Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73
   PubMed Web of Science ®Google Scholar
• Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Rusch V, Pao W, Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 2011;17:3500-6
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Douillard JY, Shepherd FA, Hirsh V, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-52
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42
   PubMed Web of Science ®Google Scholar
• Zhu CQ, da Cunha SG, Ding K, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-6
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Hwang YP, Yun HJ, Choi JH, Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 2011;55:594-605
   PubMed Web of Science ®Google Scholar
• Lev-Ari S, Starr A, Vexler A, Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res 2006;26:4423-30
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Ali S, Ali IF, Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 2006;66:10553-9
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Ali S, Philip PA, Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 2009;115:2165-76
   PubMed Web of Science ®Google Scholar
• De LA, Carotenuto A, Rachiglio A, The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-67
   Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
   PubMed Web of Science ®Google Scholar
• Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986;232:1250-3
   PubMed Web of Science ®Google Scholar
• Maity A, Pore N, Lee J, Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86
   PubMed Web of Science ®Google Scholar
• Goldman CK, Kim J, Wong WL, Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33
   PubMed Web of Science ®Google Scholar
• Pore N, Liu S, Haas-Kogan DA, PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003;63:236-41
   PubMed Web of Science ®Google Scholar
• Sini P, Wyder L, Schnell C, The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005;11:4521-32
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Solorzano CC, Harbison MT, Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35
   PubMed Web of Science ®Google Scholar
• Solorzano CC, Baker CH, Tsan R, Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001;7:2563-72
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-60
   PubMed Web of Science ®Google Scholar
• Bancroft CC, Chen Z, Yeh J, Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-48
   PubMed Web of Science ®Google Scholar